By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) To Present At The 15th Annual BIO Investor Forum 10/12/2016 10:17:23 AM
AVEO Oncology (AVEO) Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation 10/3/2016 10:39:25 AM
Struggling AVEO Oncology (AVEO) Quietly Discontinues Phase II Ficlatuzumab Study 9/12/2016 6:05:41 AM
AVEO Oncology (AVEO) To Present At The 18th Annual Rodman & Renshaw Global Investment Conference 9/6/2016 11:30:24 AM
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma 8/15/2016 11:58:09 AM
AVEO Oncology (AVEO) Reports Second Quarter 2016 Financial Results And Provides Business Update 8/4/2016 12:10:51 PM
AVEO Oncology (AVEO) To Present At The 2016 JMP Securities Life Science Conference 6/15/2016 8:06:43 AM
AVEO Oncology (AVEO) Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma 5/26/2016 11:26:45 AM
AVEO Oncology (AVEO) Announces Closing Of Private Placement And Amended Term Loan To Fund Pivotal TIVO-3 Trial And Combination PD-1 Trial Of Tivozanib In Renal Cell Cancer 5/18/2016 10:46:29 AM
AVEO Oncology (AVEO) Announces $17 Million Private Placement 5/13/2016 8:20:56 AM